Blueprint Medicines Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Blueprint Medicines (BPMC) PT Raised to $52 at Jefferies
May 4, 2017 8:24 AM EDTJefferies raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $52.00 (from $42.00) while maintaining a Buy rating.
"With add'l clinical data for 2 lead candidates (BLU-285, BLU-554) in 2017 likely to strengthen their therapeutic potential, and added clarity around approval path for... More
Blueprint Medicines (BPMC) Misses Q1 EPS by 8c
May 3, 2017 7:06 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More